Description:

GYNECOLOGIC ONCOLOGY GROUP Cycle Dose Drug Form - FORM D2R Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer NCT00565851 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA671E4E-F217-4DDB-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA671E4E-F217-4DDB-E034-0003BA12F5E7

Keywords:
Versions (3) ▾
  1. 9/19/12
  2. 1/8/15
  3. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00565851)

No Instruction available.

  1. StudyEvent: GYNECOLOGIC ONCOLOGY GROUP Cycle Dose Drug Form - FORM D2R
    1. No Instruction available.
Header
Treatment Cycle And Modification
Were there any dose modifications or additions/omissions to protocol treatment? (*)
Kg
Performance status (Zubrod)
g/dL
1000/uL
1000/uL
1000/uL
mg/dL
mg/dL

Similar models